Logo image of EVGN

EVOGENE LTD (EVGN) Stock Fundamental Analysis

NASDAQ:EVGN - Nasdaq - IL0011050551 - Common Stock - Currency: USD

1.18  +0.03 (+2.61%)

Fundamental Rating

2

Taking everything into account, EVGN scores 2 out of 10 in our fundamental rating. EVGN was compared to 566 industry peers in the Biotechnology industry. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative. EVGN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EVGN had negative earnings in the past year.
EVGN had a negative operating cash flow in the past year.
In the past 5 years EVGN always reported negative net income.
In the past 5 years EVGN always reported negative operating cash flow.
EVGN Yearly Net Income VS EBIT VS OCF VS FCFEVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -41.35%, EVGN perfoms like the industry average, outperforming 53.89% of the companies in the same industry.
Industry RankSector Rank
ROA -41.35%
ROE N/A
ROIC N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVGN Yearly ROA, ROE, ROICEVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

EVGN has a better Gross Margin (68.48%) than 80.39% of its industry peers.
In the last couple of years the Gross Margin of EVGN has declined.
The Profit Margin and Operating Margin are not available for EVGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
EVGN Yearly Profit, Operating, Gross MarginsEVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
EVGN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EVGN has less shares outstanding
The debt/assets ratio for EVGN is higher compared to a year ago.
EVGN Yearly Shares OutstandingEVGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
EVGN Yearly Total Debt VS Total AssetsEVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.01, we must say that EVGN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.01, EVGN is doing worse than 76.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.01
ROIC/WACCN/A
WACC5.72%
EVGN Yearly LT Debt VS Equity VS FCFEVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 1.15 indicates that EVGN should not have too much problems paying its short term obligations.
EVGN's Current ratio of 1.15 is on the low side compared to the rest of the industry. EVGN is outperformed by 86.75% of its industry peers.
A Quick Ratio of 1.06 indicates that EVGN should not have too much problems paying its short term obligations.
EVGN has a worse Quick ratio (1.06) than 86.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.15
Quick Ratio 1.06
EVGN Yearly Current Assets VS Current LiabilitesEVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.32% over the past year.
Looking at the last year, EVGN shows a very strong growth in Revenue. The Revenue has grown by 51.04%.
EVGN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 62.55% yearly.
EPS 1Y (TTM)41.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.62%
Revenue 1Y (TTM)51.04%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%178.72%

3.2 Future

EVGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.45% yearly.
EVGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.74% yearly.
EPS Next Y29.81%
EPS Next 2Y19.42%
EPS Next 3Y22.45%
EPS Next 5YN/A
Revenue Next Year33.67%
Revenue Next 2Y49.37%
Revenue Next 3Y55.74%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
EVGN Yearly Revenue VS EstimatesEVGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
EVGN Yearly EPS VS EstimatesEVGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EVGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EVGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVGN Price Earnings VS Forward Price EarningsEVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVGN Per share dataEVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

EVGN's earnings are expected to grow with 22.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.42%
EPS Next 3Y22.45%

More info and screens

0

5. Dividend

5.1 Amount

EVGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOGENE LTD

NASDAQ:EVGN (5/2/2025, 3:37:30 PM)

1.18

+0.03 (+2.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/bmo
Earnings (Next)05-22 2025-05-22/bmo
Inst Owners7.68%
Inst Owner Change0%
Ins Owners1.56%
Ins Owner ChangeN/A
Market Cap7.68M
Analysts82.5
Price Target5.61 (375.42%)
Short Float %0.4%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.48%
Min EPS beat(2)-27.16%
Max EPS beat(2)108.11%
EPS beat(4)3
Avg EPS beat(4)28.81%
Min EPS beat(4)-27.16%
Max EPS beat(4)108.11%
EPS beat(8)7
Avg EPS beat(8)23.38%
EPS beat(12)9
Avg EPS beat(12)20.65%
EPS beat(16)12
Avg EPS beat(16)17.37%
Revenue beat(2)0
Avg Revenue beat(2)-47.33%
Min Revenue beat(2)-56.44%
Max Revenue beat(2)-38.22%
Revenue beat(4)2
Avg Revenue beat(4)-16.32%
Min Revenue beat(4)-56.44%
Max Revenue beat(4)17.37%
Revenue beat(8)4
Avg Revenue beat(8)13.2%
Revenue beat(12)7
Avg Revenue beat(12)58.42%
Revenue beat(16)9
Avg Revenue beat(16)41.31%
PT rev (1m)-32.31%
PT rev (3m)-32.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30.82%
EPS NY rev (1m)0%
EPS NY rev (3m)31.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.44%
Revenue NY rev (1m)-3.63%
Revenue NY rev (3m)-3.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.9
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-2.18
Fwd EYN/A
FCF(TTM)-3.12
FCFYN/A
OCF(TTM)-3.03
OCFYN/A
SpS1.31
BVpS-0.22
TBVpS-2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.48%
FCFM N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25%
Cap/Sales 7.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.15
Quick Ratio 1.06
Altman-Z -11.01
F-Score3
WACC5.72%
ROIC/WACCN/A
Cap/Depr(3y)33.47%
Cap/Depr(5y)32.69%
Cap/Sales(3y)30.31%
Cap/Sales(5y)49.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.62%
EPS Next Y29.81%
EPS Next 2Y19.42%
EPS Next 3Y22.45%
EPS Next 5YN/A
Revenue 1Y (TTM)51.04%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%178.72%
Revenue Next Year33.67%
Revenue Next 2Y49.37%
Revenue Next 3Y55.74%
Revenue Next 5YN/A
EBIT growth 1Y18.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.35%
EBIT Next 3Y23.41%
EBIT Next 5YN/A
FCF growth 1Y9.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.7%
OCF growth 3YN/A
OCF growth 5YN/A